

Aiming to Become a Top Japanese Pharmaceutical Company

- 2011 Results & 2012 Outlook -

CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama

February 1/2, 2012



Forward-Looking Statements

This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the "Company"). These statements reflect the Company's current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company's businesses.




Overview of 2011

Impact of the Great East Japan Earthquake

- Production Activities
 - Loss on disaster (Extraordinary Loss): 4.7billion yen
 - Utsunomiya Plant and some of our contract manufacturers affected
 - ✓ Utsunomiya Plant: fully resumed operation by August, 2011

Sales Activities

- Shipment control on some of our products continued until end of October
 - MR activities severely disturbed during this period
- Cancellation of product launch events and other promotional activities
- Domestic sales: -4.4% (vs. previous year), -6.6% (vs. forecast)



Sales activities back to normal from November, 2011 after end of shipment control



2011 Full Year Results

Decline in both Revenues and Operating income due to the Great East Japan Earthquake


(billions of yen)	2010	2011	YoY	vs. plan
Revenues	379.5	373.5	-1.6%	-5.5%
Domestic	342.9	327.9	-4.4%	-6.6%
Overseas	36.6	45.6	+24.6%	+3.6%
Operating income	66.2	62.4	-5.7%	-13.3%
% revenues	17.4%	16.7%		
Net income	41.4	35.2	-15.0%	-4.9%
% revenues	10.9%	9.4%		

Aiming to Become a Top Japanese Pharmaceutical Company - Review of 2011 and Plans for 2012 -

CHUGAI

R&D Update: 2011 Approvals and New Development Projects

Prosperous progress ~ strong contribution from 2012~





2012 Forecast

Strong sales & profit growth from new products launches and additional indications to absorb NHI price cut impact


(billions of yen)	2011	2012 Plan	YoY
Revenues	373.5	418.5	+12.0%
Sales	363.6	403.7	+11.0%
Other operating revenues	9.9	14.8	+49.5%
SG&A	97.7	100.0	+2.4%
% of revenues	26.2%	23.9%	
R&D	55.9	60.0	+7.3%
% of revenues	15.0%	14.3%	
Operating income	62.4	80.0	+28.2%
% of revenues	16.7%	19.1%	
Net income	35.2	49.0	+39.2%
% of revenues	9.4%	11.7%	

Aiming to Become a Top Japanese Pharmaceutical Company

- Review of 2011 and Plans for 2012 -



Sunrise 2012 Assumptions



Aiming to Become a Top Japanese Pharmaceutical Company

- Review of 2011 and Plans for 2012 -



Enhancement of Sales Force

To achieve the goals of Sunrise 2012 by contributing to standardized healthcare quality and to eliminate care disparities in Japan

Oncology Unit Establish a new organization to cover the leading edge medical technology standards ->To contribute to cancer-care in Japan by uniting Research &

Development and Sales & Marketing

Establish Chugai's "Consulting Promotion" style

Achievement of Sunrise 2012 Goals

Primary Unit Reorganize Sales and Marketing <u>function</u> ->To conduct effective market penetration (Actemra, Mircera, Edirol)

• Expand coverage of Primary care MRs for all products

Creation of Medical Science Div.


- -> To reinforce the evidence creation function in post-marketing
- •Support to implement product promotion strategies
- •Timely distribution of new medical information from conferences to MDs
- Provide consistent education for MRs

- Review of 2011 and Plans for 2012 -



Avastin

22.0% sales increase, absorbing NHI price cut




- Review of 2011 and Plans for 2012 -



Epogin/Mircera

Regain the position as market leader in ESA market ~ 2012 target market share : 60% ~



Appeal monthly dosage features


- Generate publications and medical presentations to promote usage
 ✓ Switching dose information
 - ✓Injection pain comparison
 - ✓ Cost-benefit comparison

- Review of 2011 and Plans for 2012 -



Alfarol/Edirol

Appeal "Grade A" recommendation in Osteoporosis Treatment Guideline 2011 (1St & only Vitamin D3 to obtain Grade A)




Aiming to Become a Top Japanese Pharmaceutical Company

- Review of 2011 and Plans for 2012 -



Actemra




Aiming to Become a Top Japanese Pharmaceutical Company - Review of 2011 and Plans for 2012 -



Promotion of PHC Based Projects

Development based on PHC with the strength of Roche Group



Aiming to Become a Top Japanese Pharmaceutical Company - Review of 2011 and Plans for 2012 -



Utilizing Innovative Antibody Engineering Technology

Chugai Pharmabody Research Pte. Ltd.

<Purpose for Establishment>

- Generate novel therapeutic antibodies by focusing on utilization of recycling and sweeping antibody technology
- Aim to generate 20 or more antibodies in five years (five to seven antibodies per year) focusing on target antigens in disease areas such as oncology, immunology and inflammation

	Contents
Location and Reason	Singapore Chugai already has R&D experiences in Singapore with PharmaLogicals Research; attractive environment to employ PostDocs and research technicians
Number of Employees	Approx. 60 (staff/researchers from Chugai : approx.15, local employment: approx. 45)
Capital	1.5 million Singapore dollars
Business Term	5 years (planned)
Cost (5 years)	12.5 billion yen (planned)


Aiming to Become a Top Japanese Pharmaceutical Company

- Review of 2011 and Plans for 2012 -

Sweeping Antibody

Introduction of Recycling Antibody and Sweeping Antibody

Recycling Antibody



"Sweeping antibody" generated by further engineering and evolution of recycling antibody* to enhance its turnover rate, thereby enabling degradation of larger amount of antigen and eliminating (sweeping) of the antigen from the plasma.

*Recycling antibody dissociates the antigen intracellularly, recycles back extracellularly and binds to the antigen repeatedly

CHUGA

Roche Roche Group

Aiming to Become a Top Japanese Pharmaceutical Company - Review of 2011 and Plans for 2012 -



Chugai-Roche Basic Agreements

Ownership Arrangements

Period	Upper Threshold
Oct.1, 2002 – Sept. 30, 2007	50.1%
Oct.1, 2007 – Sept. 30, 2012	59.9% ownership increased from 50.1% to 59.9% in June 2008
Oct.1, 2012 and thereafter	No limit

Management Arrangements

- Chugai continues to be self-governed and Roche respects autonomy of Chugai management
- Roche to cooperate to maintain Chugai listed on the First Section of the Tokyo Stock Exchange



FY2011 Consolidated Financial Overview

CHUGAI PHARMACEUTICAL CO., LTD. Senior Vice President and CFO Yoshio Itaya

February 1, 2012



Summary

Revenues and profits declined due to negative sales growth

- Revenues: 373.5 billion JPY (-1.6%), Operating Income: 62.4 billion JPY (-5.7%)
- Tamiflu sales: significantly declined as stockpiling sales close out
- Sales excl. Tamiflu: slightly declined as the impact of the earthquake on domestic sales outweighed the growth in overseas sales
- Other Operating Revenues: increased substantially from one-time events
- Extraordinary Loss: 6.5 billion JPY
 - Loss on disaster: 4.7 billion JPY
- Year-end dividend 20 JPY per share (40 JPY annual dividend), achieving a payout ratio of 61.8 %

CHUGAI

(Billion JPY)

Financial Overview Jan - Dec

(Pillion IDV)		2010		2011		Growth	
	(Billion JPY)	Jan-Dec As % o Revenue		Jan-Dec As % of Revenues		Growin	%
Re	evenues	379.5		373.5		-6.0	-1.6
	Sales	375.6		363.6		-12.0	-3.2
	excl. Tamiflu	357.4		354.9		-2.5	-0.7
	Tamiflu	18.2		8.7		-9.5	-52.2
	Other Operating Revenues	3.9		9.9		+6.0	+153.8
Op	perating Income	66.2	17.4	62.4	16.7	-3.8	-5.7
	Non-operating Income	2.4		2.3		-0.1	-4.2
	Non-operating Expenses	3.5		1.2		-2.3	-65.7
Or	dinary Income	65.1	17.2	63.6	17.0	-1.5	-2.3
	Extraordinary Gain	0.6		0.0		-0.6	-100.0
	Extraordinary Loss	0.0		6.5		+6.5	-
Ne	et Income	41.4	10.9	35.2	9.4	-6.2	-15.0

Sales excl. Tamiflu Domestic -9.1 Overseas +6.6 Sales of Tamiflu* -9.5 Other Operating Revenues +6.0

GC33 upfront income Income related to Actemra etc.

Operating	Income	-3.8

). +2.2

Extraordinary Loss	+6.5
Loss on disaster	+4.7

Asset retirement obligations +1.0

Average ex	xchange rate (JPY)	
	2010 Jan-Dec	2011 Jan-Dec
CHF	84.17	89.86
EUR	116.32	110.92

* Tamiflu

	2010 Jan-Dec	2011 Jan-Dec	Variance
Ordinary	1.6	5.4	+3.8
Govt. Stockpile etc.	16.6	3.3	-13.3

FY2011 Consolidated Financial Overview



Sales (excl. Tamiflu) Jan - Dec

Sales (excl. Tamiflu) (Billion JPY) 354.9 (-2.5, -0.7%) 357.4 33.0 Epogin Actemra 39.6 Overseas (overseas) +7.8 -11.2 (28.8)+6.6, +20.0% (20.5)37.4 33.8 Others Pegasys 25.8 -3.6, -9.6% +5.922.8 -2.2 Mircera (8.3) (5.9)Transplant, Immunology and Infectious diseases 50.7 57.4 Kytril -3.0, -11.6% -2.1 +3.8Avastin (3.4)(56.4) Renal diseases Domestic Domestic -6.7, -11.7% Sigmart 66.2 Actemra 62.6 Sales -1.9 +3.4 Sales (11.1)(domestic) Bone and Joint 315.3 324.4 (17.5)+3.6, +5.8% -9.1, -2.8% Renagel Edirol +1.3 -1.8 (3.1)(1.3)141.2 141.9 Oncology +0.7, +0.5%Left : Sales by Disease Field Right : Sales by Product, Variance Year on Year (): FY2011 Actual Jan-Dec Jan-Dec 2010 2011



Tamiflu Sales Performance

								I	Fiscal Term	Sales									
(E	Billion JPY)	FY20	005.12	FY20	06.12	FY20	07.12	FY20	08.12	FY20	09.12	FY20	10.12	FY2011.12 FY2012.12 S		.12 Seasonal			
		Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Sales	sentinel (millions
	2004-05	23.2																24.6	1.47
	2005-06		11.9	9.9														21.8	0.92
	2006-07				3.7	5.0												8.7	1.01
	2007-08						5.2	1.4										6.6	0.66
Ordinary	2008-09								5.7	11.0								16.7	1.27
	2009-10										25.2	1.4						26.6	2.02
	2010-11												0.2	4.1				4.3	1.26
	2011-12														1.3	8.0		9.3	-
	2012-13																1.3	-	-
	Ordinary	35.1	(+26.5)	13.6	(-21.5)	10.2	(-3.4)	7.1	(-3.1)	36.2	(+29.1)	1.6	(-34.6)	5.4	(+3.8)	9.3	(+3.9)		
								1	[1
	2005-06		0.2	6.5														6.7	
	2006-07				17.9	18.9												36.8	
	2007-08						9.6	0.2										9.8	
Govt.	2008-09								1.1	14.4								15.5	
Stockpile etc.	2009-10										25.6	10.6						36.2	
	2010-11												5.9	0.5				6.4	
	2011-12														2.8	0.3		3.2	
	2012-13																0.0		
	Govt. Stockpile etc.	0.2	(+0.2)	24.4	(+24.2)	28.5	(+4.1)	1.3	(-27.2)	40.0	(+38.7)	16.6	(-23.4)	3.3	(-13.3)	0.3	(-3.0)		
		23.2	12.0	16.3	21.6	23.8	14.8	1.6	6.8	25.4	50.8	12.0	6.1	4.6	4.1	8.3	1.3	1	
	Total	35.2	(+26.6)	38.0	(+2.8)	38.7	(+0.7)	8.4			(+67.8)	18.2	0.1	8.7	7.1	9.6	1.0		


*Total patients number of the controlled samples in the infectious Diseases Weekly Report, period between late October and mid-April (between early July 2009 and mid-March 2010 for 2009/2010), published by Japan's National Institute of Infectious Diseases.

FY2011 Consolidated Financial Overview



Operating Income Jan - Dec

(Billion JPY)



(Billion JPY)	2010	2011	Growth		
	Jan-Dec	Jan-Dec	Growth	(%)	
Revenues	379.5	373.5	-6.0	-1.6	
Cost of Sales	162.4	157.5	-4.9	-3.0	
Gross Profit	217.1	216.0	-1.1	-0.5	
Sales	213.1	206.1	-7.0	-3.3	
Other Operating Revenues	3.9	9.9	+6.0	+153.8	
SG&A (excl. R&D) exp.	96.2	97.7	+1.5	+1.6	
R&D exp.	54.7	55.9	+1.2	+2.2	
Operating Income	66.2	62.4	-3.8	-5.7	

- Decrease in Gross Profit from Sales -7.0
 Decrease in Epogin and Tamiflu stockpiling sales
- Increase in Other Operating Revenues +6.0
 GC33 upfront income, income related to Actemra etc.
- Increase in SG&A (excl. R&D) exp. -1.5
 Launch of new products
- Increase in R&D exp. -1.2
 Increase in late-stage projects (CSG452, T-DM1 etc.)

FY2011 Consolidated Financial Overview



Financial Overview Oct - Dec

	2010		2011		Crowth		(Billion JPY)
(Billion JPY)	Oct-Dec	As % of Revenues	Oct-Dec	As % of Revenues	Growth	%	➤ Sales excl. Tamiflu -6.3
Revenues	103.4		97.5		-5.9	-5.7	Mircera +3.1
Sales	102.3		96.2		-6.1	-6.0	
excl. Tamiflu	100.0		93.7		-6.3	-6.3	Edirol +0.5
Tamiflu	2.3		2.4		+0.1	+4.3	
Other Operating Revenues	1.1		1.3		+0.2	+18.2	Pegasys -1.0
Cost of Sales	42.8		42.1		-0.7	-1.6	
Gross Profit	60.6	58.6	55.4	56.8	-5.2	-8.6	
SG&A (excl. R&D) exp.	24.7		28.3		+3.6	+14.6	Sales of Tamiflu* +0.1
R&D exp.	14.8	:	14.6		-0.2	-1.4	Other Operating Revenues +0.2
Operating Income	21.1	20.4	12.4	12.7	-8.7	-41.2	Increase in income related to Actemra
Non-operating Income	0.5		1.9		+1.4	+280.0	
Non-operating Expenses	0.7		1.8		+1.1	+157.1	➢ Operating Income -8.7
Ordinary Income	20.8	20.1	12.5	12.8	-8.3	-39.9	
Extraordinary Gain	0.6		0.0		-0.6	-100.0	
Extraordinary Loss	0.0		-2.6		-2.6	-	
Net Income	13.4	13.0	8.1	8.3	-5.3	-39.6	
					k	' Tamiflu	2010 2011 Oct-Dec Oct-Dec Growth
						Ordinary	0.2 1.3 +1.1
						Govt. Stoo	ckpile etc. 2.1 1.1 -1.0 23



Financial Overview Jan - Dec

						Actual	Forec	ast on Ju	ı l. 21
	Actual	Forecast on Jul. 21			(Billion JPY)	2011 Jan-Dec	2011 Jan-Dec	Variance	Achiev. (%)
(Billion JPY)	2011	2011			Sales excl. Tamiflu	354.9	374.3	-19.4	94.8
	Jan-Dec	Jan-Dec	Variance	Achiev. (%)	Oncology	141.9	150.6	-8.7	94.2
Revenues	373.5	395.2	-21.7	94.5	Avastin	56.4	62.4	-6.0	90.4
Nevenue3	373.5	395.2	-21.7	94.5	Herceptin	25.9	24.6		
Sales	363.6	384.5	-20.9	94.6	Neutrogin	9.4	10.1	-0.7	93.1
and Tamiffer	254.0	074.0	10.4		Xeloda	10.0		-1.7	85.5
excl. Tamiflu	354.9	374.3	-19.4	94.8	Tarceva	8.3	8.8		94.3
Tamiflu	8.7	10.2	-1.5	85.3	Bond and Joint	66.2	69.0	-2.8	95.9
					Evista	18.5	17.5	+1.0	105.7
Other Operating Revenues	9.9	10.7	-0.8	92.5	Actemra	17.5	19.9	-2.4	87.9
Cost of Sales	157.5	167.2	-9.7	94.2	Svenyl	13.0	13.7	-0.7	94.9
	107.0	101.2	0.7	04.2	Edirol	1.3	2.1	-0.8	61.9
Gross Profit	216.0	228.0	-12.0	94.7	Renal	50.7	58.9	-8.2	86.1
SG&A excl. R&D	97.7	98.0	-0.3	99.7	Epogin	28.8	30.5	-1.7	94.4
SOUR EXCI. NOD	57.7	90.0	-0.5	99.7	Mircera	5.9	12.4	-6.5	47.6
R&D exp.	55.9	58.0	-2.1	96.4	Transp., Immun., Infectious	22.8	25.1	-2.3	90.8
Operating Income	CO 4	70.0	0.0	00.7	Pegasys	8.3	10.3	-2.0	80.6
Operating Income	62.4	72.0	-9.6	86.7	Copegus	3.3	4.4	-1.1	75.0
Ordinary Income	63.6	73.1	-9.5	87.0	Others	33.8	33.6	+0.2	100.6
Not Incomo	25.0	27.0	1.0	05.4	Sigmart	11.1	11.6	-0.5	95.7
Net Income	35.2	37.0	-1.8	95.1	Overseas	39.6	37.2	+2.4	106.5
					Actemra	20.5	19.7	+0.8	104.1
					Neutrogin	15.6	14.1	+1.5	110.6



Impact of the Earthquake and Tax Reform

The Great East Japan Earthquake

Loss on disaster (Extraordinary Loss): 4.7 billion JPY

- Loss on buildings and equipment was less than expected as:
 - i. insurance for buildings and equipment recorded, and;
 - ii. impairment and restoration costs were revised downward
- Buildings and equipment (costs of retirement, demolition and restoration): 1.2 billion JPY after receipt of insurance of 2.2 billion JPY
- Loss on inventories, fixed costs during shut down etc.: 3.5 billion JPY after receipt of insurance of 0.8 billion

Tax Reduction Reform

One-time deterioration of deferred tax assets less than expected

- Introduction of surtaxes for reconstruction funding
- Later than expected implementation of tax reduction (original estimate: 2012, actual:2013)




Impact from Foreign Exchange

(Billion JPY)	FX impacts Jan-Jun (vs. forecast on Apr 2	FX impacts Jul-Dec (vs. forecast on Jul 21)		
	+1.0		-0.5	
Devenues	Actemra (Export)	+0.5	Actemra (Export)	-0.2
Revenues	Neutrogin (Overseas)	+0.3	Neutrogin (Overseas)	-0.2
	Other Operating Revenue	Other Operating Reven	ues	
		+0.1		-0.1
	Cost of Roche products		Cost of Roche products	
Cost of sales		-0.8		+0.2
SG&A expenses	Overseas SG&A exp., e	tc.	Unrealized profit in Inv.,	etc.
		-0.2		+0.3
Operating Income	-0.1		±0.0	
Non-operating Inc./Exp.	Gain/loss on foreign exchanges and exchang forward contracts	ge +0.1	Gain/loss on foreign exchanges and exchang forward contracts	ge +0.8
		0.1		0.0
Ordinary Income	±0.0		+0.8	

FX rate to the JPY	1CHF	1EUR
Assumption Jan – Dec as of Apr 21*	85.00	110.00
Actual Jan – Jun avg.	90.38	114.86
Assumption Jul – Dec as of Jul 21	95.00	110.00
Actual Jul – Dec avg.	89.32	107.04
Reference Actual Jan – Dec avg.	89.86	110.92

*No changes from original assumption in Feb.


[Reference]






Balance Sheet Items (Assets)

(Billion JPY)





Balance Sheet Items (Liabilities)




Accounts pa	-2.1						
Income taxe	+10.5						
Accrued pay	Accrued payables						
Accrued exp	+2.5						
Others Increase in a taxes and ree employees	accrued cons eserve for bo	•					
Equity Ratio							
Dec. 2010	Dec. 2011	Variance					
88.0%	85.6%	-2.4%pts					

FY2011 Consolidated Financial Overview

Actual 2011

Cash Flow Statement Jan - Dec



	Cash flow from operating activities	+69.6
	Income before taxes and minority interests	+57.1
	Depreciation and amortization	+15.9
	Loss on disaster	+4.7
	Increase in working capital	-1.5
	Decrease in trade notes and accounts receivable	+2.4
	Increase in inventories	-1.9
	Decrease in trade notes and accounts payable	-1.9
	Proceeds from insurance income	+3.0
	Payments for loss on disaster	-3.4
	Income taxes paid	-11.8
	Cash flow from investing activities	-15.1
	Increase in time deposits	-2.6
	Increase in marketable and investment secu	rities
		-1.3
	Purchases of noncurrent assets	-11.2
2	Cash flow from financing activities	-24.6
	Cash flow from financing activities	
	Cash dividends paid	-23.4 29





2012 Forecast Jan - Dec

	Act	ual	Fore	cast	Crow		(Billion JPY)	
(Billion JPY)	2011		2012		Growth			
	Jan-Dec	As % of Revenues	Jan-Dec	As %of Revenues		%	➤ Sales excl. Tamiflu +39.2	
Revenues	373.5		418.5		+45.0	+12.0	➤ Sales of Tamiflu +0.9	
Sales	363.6		403.7		+40.1	+11.0		
excl. Tamiflu	354.9		394.1		+39.2	+11.0		
Tamiflu	8.7		9.6	-	+0.9	+10.3		
Other Operating Revenues	9.9		14.8		+4.9	+49.5	Other Operating Revenues	
Cost of sales	157.5		178.5		+21.0	+13.3	1 0	
Gross Profit	216.0	57.8	240.0	57.3	+24.0	+11.1		
SG&A (excl. R&D) exp.	97.7		100.0		+2.3	+2.4		
R&D exp.	55.9		60.0		+4.1	+7.3		
Operating Income	62.4	16.7	80.0	19.1	+17.6	+28.2	➢ Operating Income +17.6	
Ordinary Income	63.6	17.0	80.5	19.2	+16.9	+26.6		
Net Income	35.2	9.4	49.0	11.7	+13.8	+39.2	➢ Net Income +13.8	

Exchange rate (JPY)

U	, , , , , , , , , , , , , , , , , , ,	Assumption
	2011 Jan-Dec	2012 Jan-Dec
CHF	89.86	85.00
EUR	110.92	109.00

FY2011 Consolidated Financial Overview




Sales Forecast vs. 2011 Actual

Oncology	. —				
	Avastin			+12.4	Avastin :
	Xeloda		+6.8		Increase penetration in NSCLC, BC Xeloda : Increase penetration of XELOX in CRC
Bone and Joint Actemra (domestic)			+0.8		Actemra : Growth to be maintained over NHI price revision Expand market position in the 1 st and 2 nd line Edirol :
	Edirol		+6.5		Promote switching from conventional VD emphasizing Glade A recommendation in
	Alfarol	-3.2			treatment guidelines Alfarol: To be switched to Edirol
Renal	Mircera			+23.7	Mircera : Appeal monthly dosage features by data publications (switching dosage, pain reduction,
	Epogin	-12.0			cost benefit, etc.) Epogin : To be switched to Mircera
Transp., In	n mun., Infectio u Pegasys	IS	+3.8		Pegasys : Promote monotherapy in HCV Increase market share in HBV and cirrhosis
Overseas Actem	ra (overseas)		+3.6		Actemra (overseas) : Further growth in Roche sales (launched in more than 70 countries)



Growth in Revenues and Operating Income






Dividend Policy

Policy

Aiming to ensure stable profit for all shareholders and a consolidated dividend payout ratio of <u>over 40% on average</u>, taking account of strategic funding needs and earnings prospects.





Overview of Development Pipeline

CHUGAI PHARMACEUTICAL CO., LTD. Senior Vice President Head of Lifecycle Management & Marketing Unit Yutaka Tanaka

February 1/2, 2012



Projects under Development (as of 1 Feb. 2012)

	Phase I	Phase II	Phase III
Oncology	CIF/RG7167 - solid tumors CKI27/RG7304 - solid tumors GC33 - liver cancer MRA/Actemra - PC PA799 - solid tumors WT4869 - myelodysplastic syndromes (PI/II) - solid tumors RG3638 - NSCLC	AF802 – NSCLC (PI/II) RG435/Avastin - glioblastoma (relapsed) RG1415/Tarceva - NSCLC(1 st line)	RG435/Avastin - GC - aBC - glioblastoma RG1273/pertuzumab - BC RG3502(T-DM1) - BC GA101 (RG7159)/obinutuzumab - NHL
Bone & Joint	SA237 - rheumatoid arthritis	RG484/Bonviva(oral) - osteoporosis	MRA/Actemra (overseas) - RA(sc) - SVE - enthesopathy★ RG484/Bonviva(inj) (PII/III) - osteoporosis
Others	RG1450 - Alzheimer's disease RG3637 - asthma RG7090 - major depressive disorder		tofogliflozin(CSG452) - diabetes RG1678/bitopertin - schizophrenia

Letters in orange in-house projects ★: Projects with advances in stages since Oct. 21, 2011



Development Status - Oncology



Xeloda : Xelox regimen for adjuvant colon cancer

Combination therapy with Oxaliplatin (Filed by Yakult) Approved in Nov. 2011



GA101 (RG7159) :

• 1st line aggressive NHL

Started P3 multinational study in Oct. 2011

• 1st line indolent NHL

Started P3 multinational study in Nov. 2011



Development Status - Bone & Joint



Suvenyl : Enthesopathy (Lateral epicondylitis, Patellar tendinitis, Achilles tendinopathy, Plantar fasciitis) Started P3 study in Oct. 2011

Started F5 Study In Oct. 201



Actemra (US) : Rheumatoid Arthritis

Filed sBLA in Dec. 2011 Genentech submitted a sBLA to FDA to eliminate the condition of "who have had an inadequate response to one or more TNF antagonist therapies" from the current RA indication

CHUGAI

Development Status -Transplant, Immunology, Infectious diseases



RG7128 (mericitabine): HCV

Development suspended Prioritising the R&D portfolio






Projected Submissions (Post PoC products and NMEs)

■ Continue to make filings, every year






*Overseas brand name



Enthesopathy



Enthesis is the attachment site where the tendon and ligament meets the bone.

Cause of disease

- Overuse
 - ✓ Daily life (housework, job)
 - ✓ Sports
- Aging

Pathological condition

- Degeneration of enthesis: Enthesopathy occurs around the joints throughout the body and shows same pathological condition
- Typical diseases
 - ✓ Lateral epicondylitis (tennis elbow)
 - ✓ Patellar tendinitis (jumper's knee)
 - ✓ Achilles tendinopathy
 - ✓ Plantar fasciitis
- Symptoms
 - Pain and impairment of ADL



Current Situation of the Requests Made by MHLW Unapproved Drug Committee

MHLW Unapproved Drug Committee

Requested drug manufacturers to develop unapproved drugs with high clinical needs, including 8 cases / 10 indications for Chugai

Date for request	Product	indication	Development status	
	Xeloda	Advanced or recurrent gastric cancer	Approved in Feb. 2011	
	Tarceva	Advanced or recurrent pancreatic cancer	Approved in Jul. 2011	
May 21, 2010	Avastin	Advanced or recurrent breast cancer	Approved in Sep. 2011	
	pulmozyme	Improvement of pulmonary function in patients with cystic fibrosis	Filed in Jul. 2011	
	Herceptin	Q3W dosage HER2+ metastatic breast cancer	Approved in Nov. 2011	
	Herceptin	HER2 + neo-adjuvant breast cancer		
Dec 13, 2010	Cellcept	Child kidney transplant	Approved in Sep. 2011	
	Avastin	Ovarian cancer	Planning	
	Kytril	Radiation	Approved in Dec. 2011	
	Bactramin	Prevention & treatment of pneumocystis pneumonia	Preparing for filing	

Contacts: Corporate Communications Dept.

Corporate Communications Group

Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607 e-mail: pr@chugai-pharm.co.jp

Hitoshi Aikawa, Koichi Kawahara, Kae Miyata, Hiroshi Araki

Investor Relations Group

Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607 e-mail: ir@chugai-pharm.co.jp Mac Uchida, Yumiko Watanabe, Yusuke Tokita,

Chisato Kitamura